Azithromycin (n = 42) | Placebo (n = 42) | ||
---|---|---|---|
Age (years), mean (SD) | 67 (9) | 68 (10) | |
Male sex, n (%) | 31 (74) | 32 (76) | |
FEV1 (L), mean (SD) | 1.41 (0.52) | 1.32 (0.42) | |
FEV1 %predicted, mean (SD) | 49.8 (16.4) | 47.4 (12.9) | |
FEV1/FVC ratio (%),mean (SD) | 42.2 (11.9) | 43.2 (11.7) | |
BMI (kg/m2), mean (SD) | 27.2 (4.3) | 25.7 (5.8) | |
Pack years, median (range) | 30.5 (3-110) | 30.0 (1-69) | |
Current smoker, n (%) | 14 (33) | 15 (36) | |
Blood values, | CRP (mg/L), median (range) | 6.5 (0-46) | 4.0 (0-25) |
ASAT (U/L)* mean (SD) | 24.2 (6.5) | 26.4 (9.8) | |
ALAT (U/L)* mean (SD) | 24.4 (8.0) | 24.4 (13.7) | |
LCQ scores, mean (SD) | Total | 14.5 (2.3) | 13.4 (3.3) |
Physical | 4.3 (0.7) | 4.2 (1.0) | |
Psychological | 5.1 (1.0) | 4.7 (1.1) | |
Social | 5.0 (1.1) | 4.5 (1.5) | |
Bronchiectasis, n (%) | 18 (42.9) | 16 (38.1) | |
Inhaled medication, n (%) | Long acting beta2 agonists | 34 (81.0) | 35 (83.3) |
Long acting anticholinergics | 27 (64.3) | 24 (57.1) | |
Corticosteroids | 41 (98.0) | 35 (83.0) | |
Number of exacerbations in previous year, median (range) | 1 (0-8) | 1 (0-13) |